| # | Title | Journal | Year | Citations |
|---|
| 1 | Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment | Mayo Clinic Proceedings | 2019 | 1,153 |
| 2 | PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine | Clinical Cancer Research | 2011 | 562 |
| 3 | Cytokines in Cancer Immunotherapy | Cancers | 2011 | 549 |
| 4 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study | Lancet Oncology, The | 2020 | 544 |
| 5 | Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial | Blood | 2020 | 436 |
| 6 | Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 401 |
| 7 | Global Burden of Multiple Myeloma | JAMA Oncology | 2018 | 398 |
| 8 | Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer | Journal of Clinical Oncology | 2006 | 357 |
| 9 | Diagnosis and Management of Multiple Myeloma | JAMA - Journal of the American Medical Association | 2022 | 308 |
| 10 | Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma | Cancer | 2000 | 269 |
| 11 | Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer | Journal of Clinical Investigation | 2019 | 250 |
| 12 | Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis | Lancet Oncology, The | 2019 | 247 |
| 13 | Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma | Blood | 2017 | 243 |
| 14 | Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma | Journal of Clinical Oncology | 2020 | 233 |
| 15 | High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma | Blood | 2002 | 205 |
| 16 | CC2D2A Is Mutated in Joubert Syndrome and Interacts with the Ciliopathy-Associated Basal Body Protein CEP290 | American Journal of Human Genetics | 2008 | 202 |
| 17 | Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study | Annals of Oncology | 2019 | 171 |
| 18 | T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets | Blood | 1982 | 169 |
| 19 | T-cell immunity to the joining region of p210BCR-ABL protein. | Proceedings of the National Academy of Sciences of the United States of America | 1992 | 167 |
| 20 | Effect of a Patient and Clinician Communication-Priming Intervention on Patient-Reported Goals-of-Care Discussions Between Patients With Serious Illness and Clinicians | JAMA Internal Medicine | 2018 | 162 |
| 21 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial | | 2020 | 160 |
| 22 | The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway | Oncogene | 1999 | 154 |
| 23 | Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes | Diabetes Care | 2015 | 138 |
| 24 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events | | 2020 | 138 |
| 25 | Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers | Nature Communications | 2017 | 133 |
| 26 | Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study | Cancer | 2017 | 132 |
| 27 | Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition | Science Signaling | 2019 | 130 |
| 28 | Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma | Cancer Immunology Research | 2014 | 120 |
| 29 | Interprofessional Communication Skills Training for Serious Illness: Evaluation of a Small-Group, Simulated Patient Intervention | Journal of Palliative Medicine | 2014 | 116 |
| 30 | Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors | Annals of Oncology | 2019 | 113 |
| 31 | High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults ≥ 60 Years Old With Relapsed or Refractory B-Cell Lymphoma | Journal of Clinical Oncology | 2007 | 112 |
| 32 | Racial and ethnic disparities in hematologic malignancies | Blood | 2017 | 111 |
| 33 | Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography | Cancer | 1999 | 107 |
| 34 | Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma | Blood | 2018 | 105 |
| 35 | CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity | Prostate | 2010 | 98 |
| 36 | Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? | Breast | 2015 | 97 |
| 37 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2022 | 97 |
| 38 | Microsatellite instability in prostate cancer by PCR or next-generation sequencing | | 2018 | 96 |
| 39 | Head and neck osteosarcoma at the University of Washington | | 1997 | 95 |
| 40 | An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer | JAMA Oncology | 2017 | 94 |
| 41 | Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma | Journal of Clinical Investigation | 2018 | 93 |
| 42 | Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab | Archives of Dermatology | 2007 | 92 |
| 43 | PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL | Blood Advances | 2019 | 92 |
| 44 | Germline and Somatic Mutations in Prostate Cancer for the Clinician | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 91 |
| 45 | Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer | Breast Cancer Research and Treatment | 2010 | 90 |
| 46 | Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference | JAMA Oncology | 2021 | 90 |
| 47 | A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316) | Oncologist | 2012 | 89 |
| 48 | Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer | Clinical Cancer Research | 2017 | 88 |
| 49 | Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial | Lancet Haematology,the | 2019 | 84 |
| 50 | Therapy with cultured T cells: principles revisited | Immunological Reviews | 1997 | 83 |
